Esophageal cancer: current and emerging therapy modalities
Simon Ekman, Martin Dreilich, Johan Lennartsson et al. · Expert Review of Anticancer Therapy · 2008
During the last few years, there has been a gradual increase in treatment options for patients with esophageal malignancies. Several clinical studies have been performed, covering not only radiation and chemotherapy, but also the introduction of novel biological agents into the treatment arsenal. Patients with esophageal carcinoma are now offered second-line and sometimes even third-line treatments, and the number of research protocols is increasing. Despite the newly awakened interest in this malignancy, the overall 5-year survival rate has remained at approximately 10% since the 1980s. This review contains a compilation of available studies of esophageal malignancies and discusses current treatment options as well as newly developed therapies targeted at growth factor receptors.
Cited by 47 works. doi:10.1586/14737140.8.9.1433
Authors
- Simon Ekman
- Martin Dreilich
- Johan Lennartsson
- Bengt Wallner
- Daniel Brattström
- Magnus Sundbom
- Michael Bergqvist
References
- Global cancer statistics
- Global Cancer Statistics, 2002
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Rising incidence of adenocarcinoma of the esophagus and gastric cardia
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus
- Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
- A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Hepatogastroenterology